Brief: Canbridge Pharmaceuticals Says Velaglucerase-Beta Injection Approved In China
20/05/2025 05:40
May 20 (Reuters) - Canbridge Pharmaceuticals Inc 1228.HK: VELAGLUCERASE-BETA FOR INJECTION APPROVED IN CHINA FOR GAUCHER DISEASE INJECTION APPROVED BY NMPA Further company coverage: 1228.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares